Trastuzumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Trastuzumab |
| DrugBank ID | DB00072 |
| Brand Names (EU) | Kanjinti |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.95% |
Approved Indication (EMA)
Metastatic breast cancer Kanjinti is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC): as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone-receptor positive patients must also have failed hormonal therapy, unless patients are unsuit
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | HER2 positive breast carcinoma | 99.95% | DL |
| 2 | progesterone-receptor positive breast cancer | 99.90% | DL |
| 3 | normal breast-like subtype of breast carcinoma | 99.90% | DL |
| 4 | progesterone-receptor negative breast cancer | 99.90% | DL |
| 5 | breast tumor luminal A or B | 99.90% | DL |
| 6 | malignant cutaneous granular cell skin tumor | 99.48% | DL |
| 7 | ectomesenchymoma | 99.48% | DL |
| 8 | human herpesvirus 8-related tumor | 99.46% | DL |
| 9 | middle ear neuroendocrine tumor | 99.44% | DL |
| 10 | kidney pelvis sarcomatoid transitional cell carcinoma | 99.04% | DL |
| 11 | prostatic urethra urothelial carcinoma | 99.04% | DL |
| 12 | esotropia | 99.02% | DL |
| 13 | infiltrating bladder urothelial carcinoma sarcomatoid variant | 99.01% | DL |
| 14 | renal pelvis papillary urothelial carcinoma | 98.97% | DL |
| 15 | cervical neuroblastoma | 98.75% | DL |
| 16 | schwannoma of jugular foramen | 98.74% | DL |
| 17 | benign neoplasm of buccal mucosa | 98.73% | DL |
| 18 | inner ear neoplasm | 98.72% | DL |
| 19 | benign neoplasm of hypopharynx | 98.72% | DL |
| 20 | jugular foramen meningioma | 98.71% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.